QleanAir AB (publ), the premium provider of solutions for clean indoor air, announces letters of intent from two major health systems in the US. The cleanrooms are planned to be used for a large home infusion center and for a cell therapy research lab. The letters of intent have a value of approximately USD $1,2M and $600,000 respectively, for a total of $1.8M. The two Letters of Intent are expected to turn into contracts and the order book during the autumn 2022. Both new cleanrooms are expected to complete in Q2 of 2023.

QleanAir has signed a Letter of Intent with a major health system to provide a USP 797 and USP 800 compliant cleanroom. This cleanroom will be built in a new home infusion center at a major health system in the US. QleanAir has also signed a Letter of Intent with a second major health system in the US to provide a cGMP cell therapy research laboratory cleanroom. This cleanroom will be built in an existing space and house a BSL-2 clean space.

For more information, please contact:

Christina Lindstedt, CEO E-mail christina.lindstedt@qleanair.com  Cell +46 70 677 28 77

QleanAir is a niche premium provider of clean indoor environment solutions. The company’s business model is based on lease contracts for modular solutions with a full-service offer. QleanAir solutions are developed using filter technology that traps, filters and recycles indoor air. The company has over 11,000 installed units at more than 3,000 customers on the markets for EMEA, APAC and the Americas. For full year 2021, net sales amounted to 450 MSEK and adjusted operating margin was 18.5 percent. QleanAir’s head office is in Solna in Sweden, and the share is traded on Nasdaq First North Premier Growth Market, ticker QAIR. FNCA Sweden is Certified Adviser +46 8 528 00 399. For more information go to qleanair.com.

QleanAir signs two Letters of Intent with two major US health systems for large Cleanroom projects

© Modular Finance, source Nordic Press Releases